Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

The OncFive: Top Oncology Articles for the Week of 9/14

September 20th 2025

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

FDA Approves Subcutaneous Pembrolizumab for Solid Tumors

September 19th 2025

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Path Toward Accelerated Approval of RP1 in Advanced Melanoma Remains Unclear After FDA Type A Meeting

September 18th 2025

Replimune completed a Type A meeting with the FDA following a complete response letter for RP1 in advanced melanoma.

Dr Eroglu on the Role of Triplet vs Doublet Regimens in Melanoma With Symptomatic Brain Metastases

September 15th 2025

Zeynep Eroglu, MD, discusses the implications of using triplet vs doublet regimens in patients with melanoma who have symptomatic brain metastases.

Neoadjuvant Darovasertib Produces Preliminary Responses in Uveal Melanoma

September 8th 2025

Darovasertib was safe and active in the neoadjuvant setting for patients with uveal melanoma.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Dr Tarhini on the Rationale for Studying Vidutolimod Plus Pembrolizumab in Melanoma

September 2nd 2025

Ahmad Tarhini, MD, PhD, discussed the rationale for evaluating preoperative pembrolizumab plus vidutolimod in macroscopic, resectable stage III melanoma.

FDA Grants Type A Meeting to Discuss RP1 Plus Nivolumab in Advanced Melanoma

September 2nd 2025

The FDA scheduled a Type A meeting with the developer of RP1 to discuss the CRL that was granted to RP1 plus nivolumab for advanced melanoma.

Revisit Every OncLive On Air Episode From August 2025

September 1st 2025

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2025.

Dr Nathan on the Rationale for Evaluating Roginolisib in Advanced Ocular or Uveal Melanoma

August 27th 2025

Paul Nathan, MBBS, PhD, MRCP, details the rationale for evaluating roginolisib in patients with advanced or metastatic ocular or uveal melanoma.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC

August 15th 2025

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Early Activity With Roginolisib Supports Ongoing Phase 2 OCULE-01 Trial in Metastatic Uveal Melanoma

August 15th 2025

Early data showing tolerability and improved OS with roginolisib in metastatic uveal melanoma support its ongoing evaluation in the phase 2 OCULE-01 trial.

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma

August 14th 2025

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

Dr Eroglu on Safety Considerations for Encorafenib/Binimetinib/Nivolumab in BRAF V600+ Melanoma

August 13th 2025

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases

August 13th 2025

Zeynep Eroglu, MD, discusses the potential PFS benefit with encorafenib plus binimetinib and nivolumab in BRAF V600–mutant melanoma with symptomatic brain metastases.

Dr Eroglu on the Study of Encorafenib Plus Binimetinib/Nivolumab in BRAF V600+ Melanoma With Brain Metastases

August 12th 2025

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

Imsapepimut and Etimupepimut Plus Pembrolizumab Shows Clinical Improvement in PFS for Advanced Melanoma

August 11th 2025

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

Dr Mehnert on the Rationale for Adding IL-6 Blockade to Checkpoint Inhibition in Melanoma

August 7th 2025

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma

July 30th 2025

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.